Florian Krismer

Florian Krismer

Auto-generated profile, based on publicly available information

Florian Krismer

Department of Neurology Medical University Innsbruck Innsbruck Austria

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
GHGünter U. Höglinger
Günter U. Höglinger
GRGesine Respondek
Gesine Respondek
MSMaria Stamelou
Maria Stamelou
CKCarolin Kurz
Carolin Kurz
KJKeith A. Josephs
Keith A. Josephs
FGfor the Movement Disorder Society–endorsed PSP Study Group
for the Movement Disorder Society–endorsed PSP Study Group

21 April 2022 in Movement Disorders
Verified
Journal Article
Open access
GWGregor K. Wenning
Gregor K. Wenning
ISIva Stankovic
Iva Stankovic
LVLuca Vignatelli
Luca Vignatelli
AFAlessandra Fanciulli
Alessandra Fanciulli
GCGiovanna Calandra‐Buonaura
Giovanna Calandra‐Buonaura
HKHoracio Kaufmann
Horacio Kaufmann
Background: The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.Objective: To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence‐based and consensus‐based methodology.Methods: We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference.Results: The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow.Conclusions: This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

1 March 2013 in The Lancet Neurology
Verified
Journal Article
Open access
GWGregor K Wenning
Gregor K Wenning
FGFelix Geser
Felix Geser
FKFlorian Krismer
Florian Krismer
KSKlaus Seppi
Klaus Seppi
SDSusanne Duerr
Susanne Duerr
WPWerner Poewe
Werner Poewe
Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we present the final analysis of a prospective multicentre study by the European MSA Study Group to investigate the natural history of MSA. Patients with a clinical diagnosis of MSA were recruited and followed up clinically for 2 years. Vital status was ascertained 2 years after study completion. Disease progression was assessed using the unified MSA rating scale (UMSARS), a disease-specific questionnaire that enables the semiquantitative rating of autonomic and motor impairment in patients with MSA. Additional rating methods were applied to grade global disease severity, autonomic symptoms, and quality of life. Survival was calculated using a Kaplan-Meier analysis and predictors were identified in a Cox regression model. Group differences were analysed by parametric tests and non-parametric tests as appropriate. Sample size estimates were calculated using a paired two-group t test. 141 patients with moderately severe disease fulfilled the consensus criteria for MSA. Mean age at symptom onset was 56·2 (SD 8·4) years. Median survival from symptom onset as determined by Kaplan-Meier analysis was 9·8 years (95% CI 8·1-11·4). The parkinsonian variant of MSA (hazard ratio [HR] 2·08, 95% CI 1·09-3·97; p=0·026) and incomplete bladder emptying (HR 2·10, 1·02-4·30; p=0·044) predicted shorter survival. 24-month progression rates of UMSARS activities of daily living, motor examination, and total scores were 49% (9·4 [SD 5·9]), 74% (12·9 [8·5]), and 57% (21·9 [11·9]), respectively, relative to baseline scores. Autonomic symptom scores progressed throughout the follow-up. Shorter symptom duration at baseline (OR 0·68, 0·5-0·9; p=0·006) and absent levodopa response (OR 3·4, 1·1-10·2; p=0·03) predicted rapid UMSARS progression. Sample size estimation showed that an interventional trial with 258 patients (129 per group) would be able to detect a 30% effect size in 1-year UMSARS motor examination decline rates at 80% power. Our prospective dataset provides new insights into the evolution of MSA based on a follow-up period that exceeds that of previous studies. It also represents a useful resource for patient counselling and planning of multicentre trials.

4 April 2017 in Journal of Neural Transmission
Verified
Journal Article
Open access
PDF file
BHBeatrice Heim
Beatrice Heim
FKFlorian Krismer
Florian Krismer
RMRoberto De Marzi
Roberto De Marzi
KSKlaus Seppi
Klaus Seppi
The differential diagnosis of parkinsonian syndromes is considered one of the most challenging in neurology and error rates in the clinical diagnosis can be high even at specialized centres. Despite several limitations, magnetic resonance imaging (MRI) has undoubtedly enhanced the diagnostic accuracy in the differential diagnosis of neurodegenerative parkinsonism over the last three decades. This review aims to summarize research findings regarding the value of the different MRI techniques, including advanced sequences at high- and ultra-high-field MRI and modern image analysis algorithms, in the diagnostic work-up of Parkinson’s disease. This includes not only the exclusion of alternative diagnoses for Parkinson’s disease such as symptomatic parkinsonism and atypical parkinsonism, but also the diagnosis of early, new onset, and even prodromal Parkinson’s disease.

18 April 2014 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
ISIva Stankovic
Iva Stankovic
FKFlorian Krismer
Florian Krismer
AJAleksandar Jesic
Aleksandar Jesic
Angelo AntoniniAngelo Antonini
Angelo Antonini
TBThomas Benke
Thomas Benke
OGon behalf of the Movement Disorders Society MSA (MODIMSA) Study Group
on behalf of the Movement Disorders Society MSA (MODIMSA) Study Group

17 March 2017 in Nature Reviews Neurology
Verified
Journal Article
Closed access
FKFlorian Krismer
Florian Krismer
GWGregor K. Wenning
Gregor K. Wenning